NCT00645151已完成4 期
A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Subjects Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg (Latin American Atorvastatin ATGOAL Study)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 512 人开始时间: 2004年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 512
- 试验地点
- 1
- 主要终点
- Responder rate in patients who achieved low-density lipoprotein cholesterol (LDL-C) level
研究概览
简要总结
The purpose of this study is to determine the percentage of patients who would reach a cholesterol goal after atorvastatin treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with high cholesterol eligible for treatment with baseline LDL-C level of less than or equal to 220 mg/dL
- •Willingness to follow diet
排除标准
- •Triglycerides less than or equal to 400 mg/dL
- •Hemoglobin A1c >10%
研究组 & 干预措施
High Risk
Experimental
干预措施: Atorvastatin (Drug)
Low Risk
Experimental
干预措施: Atorvastatin (Drug)
Medium Risk
Experimental
干预措施: Atorvastatin (Drug)
结局指标
主要结局
Responder rate in patients who achieved low-density lipoprotein cholesterol (LDL-C) level
时间窗: Week 8
次要结局
- Percentage of patients achieving LDL goal at 2 and 4 weeks(Weeks 2 and 4)
- Lipid changes at week 4 & 8(Weeks 4 and 8)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPDCOPD ExacerbationNCT01710488Fadoi Foundation, Italy258
已完成
4 期
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High CholesterolDyslipidemiasNCT00644670Pfizer's Upjohn has merged with Mylan to form Viatris Inc.232
已完成
4 期
Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels StudyDyslipidemiasNCT00540293Pfizer's Upjohn has merged with Mylan to form Viatris Inc.425
终止
2 期
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute PancreatitisHypertriglyceridemiaNCT04863014Regeneron Pharmaceuticals21
已完成
不适用
Real-life EValuation Of High Dose RosUvastatin in High Risk Patients After TitraTIONHypercholesterolemiaNCT00526721AstraZeneca1,482